WO2001032841A9 - Method of in vitro t cell differentiation of cd34+ progenitor cells - Google Patents
Method of in vitro t cell differentiation of cd34+ progenitor cellsInfo
- Publication number
- WO2001032841A9 WO2001032841A9 PCT/US2000/029655 US0029655W WO0132841A9 WO 2001032841 A9 WO2001032841 A9 WO 2001032841A9 US 0029655 W US0029655 W US 0029655W WO 0132841 A9 WO0132841 A9 WO 0132841A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- cells
- hematopoietic
- cγtokine
- factor
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 187
- 238000000034 method Methods 0.000 title claims abstract description 155
- 238000000338 in vitro Methods 0.000 title claims description 19
- 230000024245 cell differentiation Effects 0.000 title description 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 220
- 210000001165 lymph node Anatomy 0.000 claims abstract description 101
- 230000003394 haemopoietic effect Effects 0.000 claims abstract description 84
- 102000004127 Cytokines Human genes 0.000 claims abstract description 35
- 108090000695 Cytokines Proteins 0.000 claims abstract description 35
- 241000288906 Primates Species 0.000 claims abstract description 20
- 210000004027 cell Anatomy 0.000 claims description 320
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 102
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 102
- 102000004140 Oncostatin M Human genes 0.000 claims description 62
- 108090000630 Oncostatin M Proteins 0.000 claims description 62
- 108010002350 Interleukin-2 Proteins 0.000 claims description 50
- 108090001005 Interleukin-6 Proteins 0.000 claims description 47
- 102000000588 Interleukin-2 Human genes 0.000 claims description 42
- 108010002586 Interleukin-7 Proteins 0.000 claims description 42
- 102000004889 Interleukin-6 Human genes 0.000 claims description 39
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 39
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 39
- 102000036693 Thrombopoietin Human genes 0.000 claims description 38
- 108010041111 Thrombopoietin Proteins 0.000 claims description 38
- 239000003795 chemical substances by application Substances 0.000 claims description 38
- 102000000704 Interleukin-7 Human genes 0.000 claims description 30
- 241000700605 Viruses Species 0.000 claims description 25
- 230000004069 differentiation Effects 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 239000013598 vector Substances 0.000 claims description 18
- 238000012258 culturing Methods 0.000 claims description 17
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 16
- 230000012010 growth Effects 0.000 claims description 14
- 208000026278 immune system disease Diseases 0.000 claims description 12
- 208000032839 leukemia Diseases 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 10
- 239000013604 expression vector Substances 0.000 claims description 9
- 230000001177 retroviral effect Effects 0.000 claims description 9
- 210000005260 human cell Anatomy 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 6
- 239000013603 viral vector Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 45
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract description 6
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 54
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 54
- 230000000638 stimulation Effects 0.000 description 41
- 230000014509 gene expression Effects 0.000 description 32
- 241000725303 Human immunodeficiency virus Species 0.000 description 29
- 150000007523 nucleic acids Chemical class 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 24
- 230000004044 response Effects 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 16
- 239000012634 fragment Substances 0.000 description 15
- 108010047620 Phytohemagglutinins Proteins 0.000 description 14
- 239000002502 liposome Substances 0.000 description 14
- 239000003550 marker Substances 0.000 description 14
- 230000001885 phytohemagglutinin Effects 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 13
- 210000004698 lymphocyte Anatomy 0.000 description 13
- 108091008874 T cell receptors Proteins 0.000 description 12
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 12
- 239000000427 antigen Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 210000000987 immune system Anatomy 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 102000053602 DNA Human genes 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 229920002477 rna polymer Polymers 0.000 description 9
- -1 CD8 Proteins 0.000 description 8
- 230000000961 alloantigen Effects 0.000 description 8
- 230000000692 anti-sense effect Effects 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000005087 mononuclear cell Anatomy 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 6
- 229960001936 indinavir Drugs 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 239000003226 mitogen Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 5
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 5
- 206010061598 Immunodeficiency Diseases 0.000 description 5
- 102100034343 Integrase Human genes 0.000 description 5
- 241000713666 Lentivirus Species 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 101710149951 Protein Tat Proteins 0.000 description 5
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 5
- 238000010240 RT-PCR analysis Methods 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 238000012264 coculture process Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 238000012239 gene modification Methods 0.000 description 5
- 230000005017 genetic modification Effects 0.000 description 5
- 235000013617 genetically modified food Nutrition 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 210000002861 immature t-cell Anatomy 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000003563 lymphoid tissue Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 101710205625 Capsid protein p24 Proteins 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 102000003729 Neprilysin Human genes 0.000 description 4
- 108090000028 Neprilysin Proteins 0.000 description 4
- 101710177166 Phosphoprotein Proteins 0.000 description 4
- 101710149279 Small delta antigen Proteins 0.000 description 4
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 230000007813 immunodeficiency Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229960000814 tetanus toxoid Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000002992 thymic effect Effects 0.000 description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 3
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 3
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000001143 conditioned effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000000527 lymphocytic effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 210000001778 pluripotent stem cell Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 2
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 101710146739 Enterotoxin Proteins 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 102000028180 Glycophorins Human genes 0.000 description 2
- 108091005250 Glycophorins Proteins 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 101150052863 THY1 gene Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001246 colloidal dispersion Methods 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000147 enterotoxin Substances 0.000 description 2
- 231100000655 enterotoxin Toxicity 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 210000000267 erythroid cell Anatomy 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000000777 hematopoietic system Anatomy 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000001365 lymphatic vessel Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 239000000724 thymus hormone Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- IPJDHSYCSQAODE-UHFFFAOYSA-N 5-chloromethylfluorescein diacetate Chemical compound O1C(=O)C2=CC(CCl)=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 IPJDHSYCSQAODE-UHFFFAOYSA-N 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 241000282708 Aotus <primate> Species 0.000 description 1
- 241000282709 Aotus trivirgatus Species 0.000 description 1
- 241000282672 Ateles sp. Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102000013925 CD34 antigen Human genes 0.000 description 1
- 108050003733 CD34 antigen Proteins 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 108010032795 CD8 receptor Proteins 0.000 description 1
- 241000288950 Callithrix jacchus Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282668 Cebus Species 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102100026234 Cytokine receptor common subunit gamma Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010027044 HIV Core Protein p24 Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101001055227 Homo sapiens Cytokine receptor common subunit gamma Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 1
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 1
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100032816 Integrin alpha-6 Human genes 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241000282516 Papio anubis Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000288954 Saguinus fuscicollis Species 0.000 description 1
- 241000288961 Saguinus imperator Species 0.000 description 1
- 241000282695 Saimiri Species 0.000 description 1
- 241000282676 Sapajus apella Species 0.000 description 1
- 241000699772 Sciurus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- MXWJVTOOROXGIU-UHFFFAOYSA-N atrazine Chemical compound CCNC1=NC(Cl)=NC(NC(C)C)=N1 MXWJVTOOROXGIU-UHFFFAOYSA-N 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000012578 cell culture reagent Substances 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 208000024190 congenital T-cell immunodeficiency Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000005742 definitive hemopoiesis Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- RCRODHONKLSMIF-UHFFFAOYSA-N isosuberenol Natural products O1C(=O)C=CC2=C1C=C(OC)C(CC(O)C(C)=C)=C2 RCRODHONKLSMIF-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 208000021601 lentivirus infection Diseases 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 108700004030 rev Genes Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 108700004027 tat Genes Proteins 0.000 description 1
- 101150098170 tat gene Proteins 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/237—Oncostatin M [OSM]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Definitions
- the hematopoietic stem cell is the progenitor for all of the leukocytic and erythrocytic blood cells, including the lymphocytic and myelomonocytic lineages, as well as other types of cells such as osteoclasts. These cells provide an enormous range of functions and are believed to be the only cells that are self-regenerating and maintain their pluripotent potential during the life of the host.
- embr ⁇ ogenesis hematopoietic stem cells originate in coordinate waves within the extra-embryonic yolk sac and the fetal aortagonadomesonephros (AGM). Later, during definitive hematopoiesis, pluripotent stem cells populate the fetal liver and the bone marrow.
- one embodiment contemplated by the invention is a method for testing the effect of an agent on a hematopoietic cell, comprising the steps of co- culturing a lymph node cell in vitro with a primate hematopoietic T cell progenitor cell, contacting the hematopoietic T cell progenitor cell with an agent, and comparing the differentiation or growth of the hematopoietic T cell progenitor cell with the differentiation or growth of a control cell not contacted with the agent.
- Still another embodiment of the present invention is a kit comprising a container containing a cryopreserved lymph node cell and instructions for culture of the lymph node cell with a hematopoietic T cell progenitor cell.
- FIGURE 1 shows a graphic representation of the stages of T cell progenitor cell development as such cells would appear during FACS analysis.
- FIGURE 3 is a three dimensional FACS representation of the expression of CD3, CD4 and CD8 in a lymph node cocultured with CD34 + progenitor cells obtained from a patient with end stage HIV utilizing the methods described herein.
- CD3 * CD4 * CD8 + double positive hematopoietic T cell progenitor cells are immature T cells at an intermediate stage of differentiation which have lost expression of CD34. These cells subsequently mature into cells that are CD34 CD3 * (bright), and further express only one of the CD4 or CD8 cell surface markers. Thus, mature T cells are either positive for CD4 or CD8 which is expressed with the CD3 receptor as CD3 * CD4 + or CD3 + CD8 ⁇
- the manner in which the T cell progenitor cells are separated from other cells of the hematopoietic or other lineage is not critical to this invention.
- the stem cells may be separated as described in U.S. Patent No. 5,061,620 or U.S. Patent 5,799,944.
- a "substantially enriched" hematopoietic T cell progenitor cell population refers to a substantially homogeneous population of hematopoietic T cell progenitor cells that are substantially free from other cells with which they are naturally associated. As described in U.S. Patent Nos.
- CD16, CD19 and glycophorin are employed. These combinations of markers used to isolate hematopoietic T cell progenitor cells may vary as other markers become available.
- the hematopoietic cell composition substantially depleted of dedicated cells may then be further positively selected using a marker for Thy-1 (CD90), whereby a substantially homogeneous stem cell population is achieved.
- a progenitor cell population is a population which is CD34 * Thy-1 ⁇ which approximates the substantially homogeneous stem cell composition.
- the CD34 + molecule is a single chain type I transmembrane glycoprotein serving as a differentiation stage- specific receptor which is associated with hematopoietic T cell progenitor cells, stromal cell precursors, and microvascular endothelial cells.
- the CD34 + stem cell population is composed of a heterogeneous mixture of cell types, the major fraction represent committed progenitor cells and a minor fraction of CD34 * stem cells remain capable of generating hematopoietic T cell progenitor cells in long term culture.
- bone marrow is used as the source for the CD34 + cells.
- CD34 + cells are purified from peripheral blood mononuclear cells (PBMC).
- T cells Coculture of hematopoietic T cell progenitor cells with lymph node cells results in an expansion in the number of cells and in the differentiation of cells into hematopoietic cells at all stages including mature T cells that are either CD3 * CD4 + CD8 or CD3 + CD4CD8 ⁇
- T cells mature in the th ⁇ mus, and then once mature, they emigrate out of the thymus to populate secondary lymphoid tissue, consisting of the lymph nodes (LNs) and lymphatic vessels.
- LNs lymph nodes
- lymphatic vessels In vivo, LNs are normally found in locations such as the neck, axilla, abdomen, and groin, and are responsible for immune surveillance.
- a LN is an aggregation of lymphoid tissue (stroma) surrounded by a fibrous capsule that is found along the course of lymphatic vessels.
- the outer cortex contains populations of B lymphocytes within germinal center follicles, whereas the paracortical cords contain transiting T lymphocytes and antigen presenting cells (APCs).
- APCs antigen presenting cells
- Lymphoid cells can be derived from the disaggregation of a piece of lymph node.
- lymphoid cells can be derived from a LNF from which the lymph cells have migrated during tissue culture. Lymphoid cells migrating from LN material often form a monola ⁇ er of cells surrounding the isolated LN material. This phenomenon is known as "skirting". Lymphoid cells may include, but are not limited to, all cell types present in the lymph node which are not lymphocytes or lymphocytic precursors or progenitors.
- the lymph node cells are used to stimulate the T cell progenitor cells by coculturing the lymph node cells together with the T cell progenitor cells. In general, direct contact may be used for efficient stimulation.
- the lymph node cells may be obtained from the lymph nodes of a mammal at any time after the organ has developed to a stage at which it can support the differentiation of cells.
- the lymph node cells can also be grown as a monolayer.
- a monola ⁇ er is an nonconfluent layer of lymph node cells, a confluent layer of lymph node cells having a thickness of a single cells, or a confluent la ⁇ er of I ⁇ mph node cells where the cells are stacked on one another to a thickness of two or more cells.
- the monola ⁇ er is formed of cells disaggregated from their native tissue structure, which are then plated on a vessel and allowed to attach to a surface.
- a lymph node cell line can be established and used to differentiate T cell progenitor cells.
- the cell line can be human, or derived from another mammalian species.
- the LN material may be cr ⁇ opreserved for storage and shipment to remote locations, such as for use in kits.
- Cells may be cryopreserved by suspending the cells in a cr ⁇ opreservation medium and freezing the cell suspension.
- the cell suspension is generally frozen gradually and then stored in liquid nitrogen or at an equivalent temperature in a medium containing serum and a cryopreservative such as dimethyl sulfoxide (DMSO).
- DMSO dimethyl sulfoxide
- Coculture media are commercially available and can be used during the coculture process.
- suitable media include Dulbecco's Modified Eagle Medium (dMEM), Iscove s medium, and the like.
- Coculture media is frequently supplemented with serum, usually fetal bovine serum, generally at a concentration of from about 1-15%, preferably about 5%, vitamins, non-essential amino acids, and other cell culture reagents.
- serum usually fetal bovine serum
- serum usually fetal bovine serum
- vitamins, non-essential amino acids, and other cell culture reagents for example, appropriate antibiotics to prevent bacterial growth and other additives, such as p ⁇ ruvate (0.1-5 mM), glutamine (0.5-5 mM), 2- mercaptoethanol (1-10 x 10 s M) ma ⁇ also be included.
- the pH of the media ranges from about 6.0 to 8.0, but is preferabl ⁇ 7.4 after 5% C0 2 equilibration.
- the osmolarity of the media ranges from 200 to 1000 mOsm, and in one embodiment is about 290-300 mOsm.
- the temperature of the media ranges from 30 to 40°C, and in one embodiment is 37°C.
- the cells ma ⁇ be cultured in the presence of a mitogenic agent.
- a mitogenic agent is an agent capable of supporting the expansion of a population of hematopoietic T cell progenitor cell descendants when incubated or cultured with these cells. These agents include, but are not limited to lectins, such as concavalin A and ph ⁇ tohemagglutini ⁇ .
- a cytokine is included during the coculture process.
- the term "cytokine" is used as a generic name for a diverse group of soluble proteins, peptides, and polypeptides, which act as humoral regulators at nano- to picomolar concentrations and which, either under normal or pathological conditions, modulate the functional activities of individual cells and tissues.
- C ⁇ tokines comprise interleukins, initiall ⁇ thought to be produced exclusively b ⁇ leukocytes; lymphokines, initiall ⁇ thought to be produced exclusively by lymphoc ⁇ tes; monokines, initiall ⁇ thought to be produced exclusively by monoc ⁇ tes; interferons, initially thought to be involved in antiviral responses; colony stimulating factors, initiall ⁇ thought to support the growth of cells in semisolid media; and chemokines, thought to be involved in chemotaxis; and a variety of other proteins. Cytokines also comprise thymic hormones. Thymic hormones are postulated to promote T cell maturation.
- thymosin th ⁇ mopoietin
- th ⁇ mulin th ⁇ mic humoral factor.
- c ⁇ tokines In vivo, the expression of most c ⁇ tokines is strictly regulated; these factors are usually produced only b ⁇ activated cells in response to an induction signal.
- c ⁇ tokines examples include: tumor necrosis factor, transforming growth factor- ⁇ , I ⁇ mphotoxin, migration inhibition factor, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL- 13, IL-14, IL-15, various FLT receptor ligands such as fit 3, granuloc ⁇ te-macrophage colon ⁇ stimulating factor (GM-
- a combination of cytokines is included during the coculture process into combinations or cocktail formulations.
- the cocktails include: (1) IL-2; (2) IL-2 and IL-6 and oncostatin M (OSM); (3) IL-2, IL-6, IL-7, OSM, and stem cell factor (SCF); (4) IL-2, IL-6, IL-7, OSM, SCF, fit 3; (5) IL-2, IL-6, IL-7, OSM, SCF, fit 3, and thrombopoietin (TPO); (6) IL-2, IL-6, IL-7, SCF, fit 3, and TPO, and leukemia inhibitor ⁇ factor
- the factors which are emplo ⁇ ed may be naturally occurring or s ⁇ nthetic, e.g., prepared recombinantl ⁇ , and ma ⁇ be human or of other species, e.g., non-human primate or murine.
- a human cytokine is used.
- the amount of the cytokine factors will generally be in the range from about 0.1 ng/ml to 1000 ng/ml.
- a range from about 1 ng/ml to 100 ng/ml, and preferabl ⁇ from about 5 ng/ml to 50 ng/ml is used with the methods described herein.
- a population of cells is incubated with one or more probes that are each labeled with a different fluorescent tag.
- the different fluorescent tags each emitted a unique fluorescent signal that is used to differentiate the binding of one probe to a specific target on a cell.
- a marker for T cells generally, CD4, a marker for the T helper cell, and CD8, a maker for the T cytol ⁇ tic cell, it is possible to monitor the differentiation of CD34 + cells into T cells. It is also possible to assa ⁇ various c ⁇ tokines for their effectiveness as potential T cell differentiating cytokines.
- lymph node mononuclear cells LNMC
- peripheral blood mononuclear cells PBMC
- stem cells CD34 + cells
- LNMC lymph node mononuclear cells
- PBMC peripheral blood mononuclear cells
- CD34 + cells CD34 + cells
- CD1A CD3, CD4, CD5, CD8, CD10, CD11c, CD13, CD14, CD16, CD19, CD25, CD26, CD27, CD28, CD34, CD44, CD45RA, CD45R0, CD49f,d, CD51, CD56, CD57, CD62L, CD90, CD117, CD132, TCR ,TCR , HLA-DR, CCR5, CXCR4 or the appropriate immunoglobulin isotype controls.
- CMFDA labeled CD34 * cells
- flow c ⁇ tometr ⁇ are also analyzed by flow c ⁇ tometr ⁇ .
- TREC molecules in a cell decreases with each cell division.
- T cells that have few TREC molecules are likely to have undergone multiple cell divisions and may represent residual mature T cells within the LN material used in the coculture process as these cells are older than the population of T cells differentiated de novo from the progenitor cell population.
- T cells that contain relatively higher numbers of TREC are more likely to have differentiated from CD34 * progenitor cells.
- an assa ⁇ that can determine the number of TREC in a cell can be used to determine the age of a T cell population.
- the TREC assa ⁇ exploits PCR technolog ⁇ to amplif ⁇ TREC sequences to determine the number of TREC in a target cell populations.
- a general TREC protocol is described in Douek DC, et al., Nature 396(6712):690-5 (1998).
- a retroviral vector capable of integration into a host cell genome is introduced to the population of CD34 * cells before coculture with the LN material. Methods of nucleic acid introduction into a target cell are discussed herein.
- the retroviral vector contains one or more markers which can be used to discriminate between CD3 + cells that differentiated from a CD34 * cell introduced during the coculture procedure, and any CD3 + cells that might have been present in the LN material when it was taken from the host.
- the act of evaluating the cocultured population of T cells for the presence of previousl ⁇ matured CD3 + cells can occur b ⁇ screening for a marker or unique sequence contained within the retroviral vector using standard techniques well known in the art.
- lymphoc ⁇ te responses to recall antigens such as Candida and tetanus toxoid can be used in the I ⁇ mphoc ⁇ te proliferation assa ⁇ (LPA) discussed below.
- LPA I ⁇ mphoc ⁇ te proliferation assa ⁇
- neoantigens can be introduced to the developing T cells during culture, the neoantigen can be used in the LPA to then examine the abilit ⁇ of the differentiated T cells to respond to novel, s ⁇ nthetic antigens.
- recombination activation gene anal ⁇ sis is contemplated for use with the methods described herein.
- the hematopoietic T cell progenitor cells or descendants thereof ma ⁇ be genetically modified b ⁇ contacting the cells with a nucleic acid sequence capable of genetically modifying the hematopoietic T cell progenitor cells or descendants thereof.
- the resulting cells may then be grown under conditions as described for unmodified hematopoietic T cell progenitor cells, whereby the modified hematopoietic T cell progenitor cells may be expanded and differentiated and used for a variety of purposes.
- Genetic modification of a hematopoietic T cell progenitor cell includes all transient and stable changes of the cellular genetic material that are created by the exogenous addition of a nucleic acid sequence. Techniques for the modifying the progenitor cells by introducing nucleic acid sequences into
- a polynucleotide or "a nucleic acid sequence” refers to a polymeric form of nucleotides at least 10 bases in length.
- isolated nucleic acid sequence is meant a polynucleotide that is not immediately contiguous with both of the coding sequence with which it is immediatel ⁇ contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived.
- Nucleic acid sequences which encode a polypeptide of interest, or functional fragment thereof, can be operativel ⁇ linked to expression control sequences.
- “Operativel ⁇ linked” refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner.
- An expression control sequence operativel ⁇ linked to a coding sequence is ligated such that expression of the coding sequence is achieved under conditions compatible with the expression control sequences.
- expression control sequences refers to nucleic acid sequences that regulate the expression of a nucleic acid sequence to which it is operativel ⁇ linked.
- Expression control sequences are operativel ⁇ linked to a nucleic acid sequence when the expression control sequences control and regulate the transcription and, as appropriate, translation of the nucleic acid sequence.
- expression control sequences can include appropriate promoters, enhancers, transcription terminators, a start codon (i.e., ATG) in front of a protein-encoding gene, splicing signals for introns, maintenance of the correct reading frame of that gene to permit proper translation of the mRNA, and stop codons.
- control sequences is intended to include, at a minimum, components whose presence can influence expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.
- Expression control sequences can include a promoter.
- promoter minimal sequence sufficient to direct transcription. Also included in the definition are those promoter elements which are sufficient to render promoter-dependent gene expression controllable for cell- t ⁇ pe specific, tissue-specific, or inducible by external signals or agents; such elements may be located in the 5' or 3' regions of the gene. Both constitutive and inducible promoters, are included in the invention (see e.g., Bitter et al., Methods in Enzymology 153:516-544, 1987).
- Promoters derived from the genome of mammalian cells e.g., metallothionein promoter
- mammalian viruses e.g., the retrovirus long terminal repeat; the adenovirus late promoter; the vaccinia virus 7.5K promoter
- Promoters produced b ⁇ recombinant DNA or synthetic techniques may also be used to provide for transcription of the nucleic acid sequences of the invention.
- DNA has been integrated, and against cells which have not integrated the DNA construct.
- markers exist, particularly antibiotic resistance markers, such as resistance to G418, hygrom ⁇ cin, and the like. Less convenientl ⁇ , negative selection ma ⁇ be used, where the marker is the HSV tk gene, which will make the cells sensitive to agents, such as ac ⁇ clovir and ganc ⁇ clovir.
- multiple drug resistance gene(s), e.g., pgp ⁇ ma ⁇ be introduced to protect the cells against c ⁇ totoxic drugs.
- nucleic acid sequences which provide resistance to viral infection or viral replication can be introduced. In one nonlimiting example, nucleic acid sequences which provide resistance to an immunodeficiency lentivirus infection such as HIV can be introduced.
- nucleic acid sequences include antisense and ribozyme sequences.
- the transcription of ribozymes has been shown to protect against viral infection, or viral replication of an immunodeficienc ⁇ lentivirus (Rosenzweig, M. etal, Blood 90:4822-4831, 1997).
- a number of nucleic acid sequences are contemplated for use with the present invention.
- a suitable nucleic acid sequence for introduction into a CD34 * cell is a sequence whose expression or presence within the host CD34 * cell results in an increase in the viabilit ⁇ of the host cell.
- an antisense sequence that is complementar ⁇ to the tat/rev Exon I is introduced into a cell infected with the HIV virus, the product of this nucleic acid sequence produces an short segment of antisense nucleic acid that interferes with the expression of both the tat and rev genes.
- the interference generated b ⁇ the antisense sequences protects the host cell and other cells b ⁇ limiting viral reproduction.
- retroviral vectors may be emplo ⁇ ed for genetic modification.
- Combinations of retroviruses and an appropriate packaging line, where the capsid proteins will be functional for infecting cells of a primate, such as a human, can be utilized.
- Various amphotropic virus-producing cell lines are known, such as PA12 (Miller et al., Mol.
- the preferred colloidal system of this invention is a liposome.
- Liposomes are artificial membrane vesicles that are useful as delivery vehicles in vitro and in vivo. It has been shown that large u ⁇ ilamellar vesicles (LUV), which range in size from 0.2-4.0 m can encapsulate a substantial percentage of an aqueous buffer containing large macromolecules. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley et al., Trends Biochem. Sci., 6:77, 1981).
- LUV large u ⁇ ilamellar vesicles
- liposomes In addition to mammalian cells, liposomes have been used for delivery of pol ⁇ nucleotides in plant, ⁇ east and bacterial cells. In order for a liposome to be an efficient gene transfer vehicle, the following characteristics should be present: (1) encapsulation of the genes of interest at high efficienc ⁇ while not compromising their biological activity; (2) preferential and substantial binding to a target cell in comparison to non-target cells; (3) delivery of the aqueous contents of the vesicle to the target cell c ⁇ toplasm at high efficienc ⁇ ; and (4) accurate and effective expression of genetic information (Mannino et al, Bio techniques, 6:682, 1988).
- the composition of the liposome is usuall ⁇ a combination of phospholipids, particularly high-phase-transition- temperature phospholipids, usuall ⁇ in combination with steroids, especiall ⁇ cholesterol. Other phospholipids or other lipids ma ⁇ also be used.
- the physical characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations. Examples of lipids useful in liposome production include phosphatidyl compounds, such as phosphatid ⁇ lgl ⁇ cerol, phosphatidylcholine, phosphatidylserine, phosphatid ⁇ lethanolamine, sphingolipids, cerebrosides, and gangliosides.
- diacylphosphatid ⁇ l-gl ⁇ cerols where the lipid moiet ⁇ contains from 14-18 carbon atoms, particularly from 16-18 carbon atoms, and is saturated.
- Illustrative phospholipids include egg phosphatidylcholine, dipalmito ⁇ lphosphatid ⁇ lcholine and distearoylphosphatidylcholine.
- the targeting of liposomes can be classified based on anatomical and mechanistic factors. Anatomical classification is based on the level of selectivity, for example, organ-specific, cell-specific, and orga ⁇ elle-specific. Mechanistic targeting can be distinguished based upon whether it is passive or active.
- Passive targeting utilizes the natural tendency of liposomes to distribute to cells of the reticulo-endothelial system (RES) in organs which contain sinusoidal capillaries.
- Active targeting involves alteration of the liposome b ⁇ coupling the liposome to a specific ligand such as a monoclonal antibod ⁇ , sugar, glycolipid, or protein, or by changing the composition or size of the liposome in order to achieve targeting to organs and cell types other than the naturally occurring sites of localization.
- Also provided here is a method of treating a subject having an immune disorder, by culturing a lymph node cell in vitro with a primate hematopoietic T cell progenitor cell to produce a descendent cell, and then administering a therapeuticall ⁇ effective amount of the T cell progenitor cell or a descendent thereof to the subject.
- B ⁇ subject is meant an ⁇ mammal, preferabl ⁇ a primate, more preferabl ⁇ a human.
- a therapeuticall ⁇ -effective dose of hematopoietic T cell progenitor cells refers to that amount of hematopoietic T cell progenitor cells or descendants thereof that is of sufficient quantit ⁇ to alleviate a s ⁇ mptom of the disease or to ameliorate the immune disorder.
- “Ameliorate” refers to lessening or lowering the disease's or disorder's detrimental effect in the patient receiving the therapy. In the case of an immunodeficiency, (e.g., AIDS), the treatment can increase the number
- Immune disorders include "immunodeficienc ⁇ disorders" and " immunoproliferative" disorders, described above.
- An example of an immunodeficienc ⁇ disorder is AIDS, and an example of an immunoproliferative disorder is a I ⁇ mphoma.
- a patient's own T cell progenitor cells can be removed, expanded and/or differentiated, and optionally genetically altered. The cells can then be reintroduced into the patient.
- transplantation treatments described can be used in conjunction with standard viral or anti-HIV treatments.
- transplantation as described above would be accompanied b ⁇ on-going antiviral treatments and more specifically anti-HIV-1 treatments.
- the hematopoietic T cell progenitor cells may be administered in any physiologically acceptable medium, normally intravascularl ⁇ , although the ⁇ ma ⁇ also be introduced into bone or other convenient site, where the cells ma ⁇ find an appropriate site for further differentiation or for activation.
- the cells can be introduced into a I ⁇ mph node or the spleen.
- Usuall ⁇ at least 1x10 s cells will be administered, preferably 1x10 6 or more.
- Transplantation or implantation is typically by simple injection through a h ⁇ podermic needle having a bore diameter sufficient to permit passage of a suspension of cells therethrough without damaging the cells.
- the cells ma ⁇ be introduced b ⁇ injection through a h ⁇ podermic needle, catheter, or the like.
- factors ma ⁇ also be included, such as the c ⁇ tokines IL-2, IL-6, leukemia inhibitory factor (LIF), IL-7, stem cell factor (SCF), fit 3, oncostatin M (OSM), and thrombopoietin (TPO), and others.
- nucleic acid sequences into the progenitor cells or descendants thereof can be used for a wide variet ⁇ of purposes, such as gene therap ⁇ , introduction of novel capabilities into the hematopoietic T cell progenitor cells, virus resistance, enhancement of maturation to a particular subset, or the like.
- genes specific for hematopoietic cells, including combined immunodeficienc ⁇ and leukemia. These diseases ma ⁇ be treated b ⁇ homologous recombination, where at least one cop ⁇ of the defective gene ma ⁇ be modified to the wild-t ⁇ pe or a functioning gene. It ma ⁇ be necessar ⁇ to correct onl ⁇ one cop ⁇ to sufficientl ⁇ provide for therapeutic treatment of such disorders.
- therap ⁇ involves removal of bone marrow or another source of hematopoietic T cell progenitor cells from a human host, isolating the hematopoietic T cell progenitor cells from the source and expanding and differentiating the cells.
- the host ma ⁇ be left intact, or ma ⁇ be treated to substantially or complete ablate native hematopoietic capability.
- the hematopoietic T cell progenitor cells ma ⁇ be modified so as to provide for hematopoietic T cell progenitor cells having the desired genetic modification.
- the modified hematopoietic T cell progenitor cells or descendants thereof are then restored to the host to provide for the new capabilitiesit ⁇ . If necessar ⁇ , the process may be repeated to ensure the substantial absence of the original hematopoietic T cell progenitor cells and the substantial population of the modified hematopoietic T cell progenitor cells and descendants thereof.
- lymph node tissue can be conditioned in vivo to induce the proliferation or differentiation of progenitor cells b ⁇ the administration of c ⁇ tokines.
- the cocktails include: (1) IL-2; (2) IL- 2, IL-6 and OSM; (3) IL-2, IL-6, IL-7, OSM, and SCF; (4) IL-2, IL-6, IL-7, OSM, SCF, fit 3; (5) IL-2, IL-6, IL-7, OSM, SCF, fit 3, and TPO; (6) IL-2, IL-6, IL-7, OSM, SCF, fit 3, TPO, and LIF; and (7) IL-2, IL-6, and LIF.
- Alternative combinations of these cocktails are also contemplated for use with the methods described herein.
- the cytokine compositions described above are preferably prepared and administered in dose units. "Administering" the compositions ma ⁇ be accomplished b ⁇ an ⁇ means known to the skilled artisan. Solid dose units are tablets, capsules and suppositories. For treatment of a subject, depending on activit ⁇ of the compound, manner of administration, nature and severity of the disorder, age and body weight of the patent, different doses are necessar ⁇ . Under certain circumstances, however, higher or lower doses ma ⁇ be appropriate. The administration of the dose can be carried out both b ⁇ single administration in the form of an individual dose unit or else several smaller dose units and also b ⁇ multiple administration of subdivided doses at specific intervals.
- compositions ma ⁇ be administered locally or s ⁇ stemicall ⁇ .
- the compositions can be administered b ⁇ injection.
- the compositions according to the invention are preferabl ⁇ administered intravenousl ⁇ .
- other routes of administration are within the scope of the invention.
- the compositions can be administered topicall ⁇ , intravenousl ⁇ , orall ⁇ or parenterall ⁇ or as implants, but even rectal use is possible in principle.
- Suitable solid or liquid pharmaceutical preparation forms are, for example, granules, powders, tablets, coated tablets, (micro) capsules, suppositories, s ⁇ rups, emulsions, suspensions, creams, aerosols, drops or injectable solution in ampule form and also preparations with protracted release of active compounds, in whose preparation excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners or solubilizers are customaril ⁇ used as described above.
- the compositions are suitable for use in a variet ⁇ of drug deliver ⁇ s ⁇ stems.
- a method for testing the effect of an agent on cells is provided.
- agent as used herein describes any molecule, e.g., a protein, peptide, pharmaceutical or biological agent with the capability of altering growth or differentiation of hematopoietic T cell progenitor cells.
- the agent can be an ⁇ thing known to be or suspected of being capable of affecting the growth and development of T cells. These agents include s ⁇ nthetic chemical agents, biochemical agents, cells, extracts, and homogenates.
- the test agent ma ⁇ also be a combinatorial librar ⁇ for screening a plurality of compounds.
- Compounds identified can be further evaluated, detected, cloned, sequenced, and the like, either in solution of after binding to a solid support, by an ⁇ method usuall ⁇ applied to the detection of a specific DNA sequence, such as PCR, oligomer restriction (Saiki et al., Bio/Technology 3:1008- 1012, 1985), allele specific oligonucleotide (ASO) probe anal ⁇ sis (Conner et al., Proc. Natl. Acad. Sci. USA 80:278, 1983), oligonucleotide ligation assa ⁇ s (OLAs) (Landegren et al., Science 241:1077, 1988), and the like.
- PCR oligomer restriction
- ASO allele specific oligonucleotide
- OVAs oligonucleotide ligation assa ⁇ s
- the coculture of the I ⁇ mph node cells and hematopoietic T cell progenitor cells can be carried out in the presence of the agent.
- “Incubating” includes conditions which allow contact between the test compound and the hematopoietic T cell progenitor cells and descendants thereof.
- Contacting includes in solution and solid phase.
- the growth and/or differentiation of the progenitor cells, or descendants thereof, contacted with the agent is then compared to the growth or differentiation of control progenitor cells or descendants thereof as a determination of the effect of the agent.
- the control cells can be a control culture subject to otherwise identical conditions, but without the agent. Other suitable controls can readil ⁇ be determined b ⁇ one of skill in the art.
- control cells can be incubated with a vehicle, or can be incubated with a different dose of the agent, or can be incubated with an agent of known effect and activit ⁇ .
- a time course, wherein the cells are exposed to an agent for varying amounts of time, can also be performed.
- a study wherein cells are exposed to different concentrations of an agent can be performed.
- kits may comprise a carrier means containing one or more container means such as vials, tubes, and the like, each of the container means comprising one of the separate elements to be used in the method.
- the kit includes a cryopreserved sample of I ⁇ mph node or a cr ⁇ opreserved sample of a suspension of I ⁇ mph node cells, together with instructions for co-culturing such cells with hematopoietic T cell progenitor cells.
- the instructions ma ⁇ be specific to primate cells, such as human cells.
- the kit ma ⁇ also contain a container comprising one or more c ⁇ tokines, or a combination of c ⁇ tokines.
- a c ⁇ tokine combination comprises at least IL-2 and IL-6.
- the c ⁇ tokine combination ma ⁇ further comprise leukemia inhibitor ⁇ factor (LIF), stem cell factor (SCF), fit 3, thrombopoietin (TPO), oncostatin M (OSM), or IL-7.
- LIF leukemia inhibitor ⁇ factor
- SCF stem cell factor
- TPO thrombopoietin
- OSM oncostatin M
- IL-7 More than one container containing different c ⁇ tokines, or c ⁇ tokine combinations, can be included in the kit.
- Bone marrow is one of the richest source of CD34 * cells (1-3% in normal adult individuals).
- U.S. Patent No. 5,766,944 describes a method for purification of CD34 * cells from bone marrow. Briefly, bone marrow aspirates were obtained from a human source using standard techniques well known in the art, and diluted 1:2 with sterile PBS or normal saline and mixed gently. Depletion of red blood cell/high densit ⁇ cells was accomplished b ⁇ the addition of an equal volume of 3% gelatin that was mixed gentl ⁇ and allowed to settle b ⁇ gravity sedimentation. Sedimentation time may vary with different donors and the qualit ⁇ of the marrow aspirate.
- DMEM Eagle's medium
- RPMI-10 Grand Island, N.Y.
- the ficoll-h ⁇ paque gradient was then centrifuged at 1350 rpm (400 g) at room temperature (22°C) for 35 minutes. Then, the interface mononuclear cells were harvested with a pipette.
- the mononuclear cells were then diluted with an equal volume of PBS, spun at 1000 rpm for 10 minutes, and the supernatant was aspirated and discarded. The cells were resuspended in PBS +2% FCS, spun and aspirated two more times. The mononuclear marrow cells were resuspended in 5 ml RPMI and counted. The mononuclear marrow cell concentration was then adjusted to 10 x 10 6 cells/ ml with RPMI-5% HI-ADS-FCS (note-maximum of 70 x 10 6 cells/tube).
- a 0.14M 2-aminoeth ⁇ lisothiouronium bromide (AET) solution was prepared and mixed 4:1 with sedimented red blood cells (SRBC) and incubated at 37°C for twenty minutes.
- the AET treated SRBC's (AET-SRBC) was then washed four times with PBS.
- a 1 % AET-SRBC solution was prepared b ⁇ diluting 0.5 ml of packed AET-SRBC with 50 ml PBS.
- An equal volume of the 1 % AET-SRBC solution was then added to the mononuclear marrow cell suspension and the mixture was incubated at 37°C for 5 minutes. The cell mixture was then centrifuged at 600 rpm for 5 minutes then incubated at 4°C for 60 minutes.
- a 2% AET-SRBC solution mixed with a cell suspension of 2.5 x 10 6 cells/ml was used to deplete CD3 + T cells.
- a sample of the rosetting cells was checked under the microscope as rapid rosetting with large agglutination to entrap non-T cells, the percent rosetting should not exceed that of a t, sample.
- the cells were gentl ⁇ resuspended so as not to shear the CD2/CD58 complex between T cells/SRBC.
- the cell suspension was gentl ⁇ underlaid with a volume of ficoll-h ⁇ paque which was 2 times the cell suspension volume.
- the ficoll-h ⁇ paque gradient was centrifuged at 600 rpm for 10 minutes and then at 1350 rpm for 25 minutes.
- the T cells were located in the pellet and the non-T cells (B cells, macrophages/dendritic cells, mixed stem cell population including CD34 * cells) were located at the interface.
- the interface mononuclear cells was harvested with a pipette.
- the cells were diluted with an equal volume of PBS, centrifuged at 1000 rpm for 10 minutes, aspirated and the supernatant was discarded.
- the wash step was repeated.
- the cells were resuspended in 2-3 ml complete media and a cell count was performed.
- the CD34 + cell recover ⁇ was calculated. An aliquot was reserved for Colon ⁇ Forming Unit Assa ⁇ s/phenot ⁇ ping in a separate tube with complete media.
- the CD34 + cells typically display sheared epitopes and/or down regulation of the receptor induced by the binding of the capture antibody.
- the CD34 * receptor recycles within 24-36 hours after binding to the capture antibody in the selection process. The aliquot reserved for phenot ⁇ ping should therefore be rested prior to testing. There ma ⁇ be considerable variability in detection of the CD34 receptor among different mAb ⁇ -CD34 used for FACS anal ⁇ sis.
- the epitope which has provided an even performance is the HPCA-2 (8G12 clone).
- the CD34 + cells were now read ⁇ to be used. If the CD34 + cells are to be co-cultivated with lymphoid cells, the absolute minimal stem cell concentration should be about 10,000 cells per fragment/monola ⁇ er. The cells will undergo a rapid expansion during the initial phase of the coculture reflecting the expansion and terminal differentiation of the pre-committed progenitors in the CD34 + population. At set intervals of the coculture, prior to functional testing or phenot ⁇ ping these "non mononuclear" cells were removed after cell harvesting b ⁇ low densit ⁇ cell centrifugation with ficoll-h ⁇ paque.
- PBMCs peripheral blood mononuclear cells
- F/H ficoll-h ⁇ paque centrifugation as described above.
- PBMC peripheral blood mononuclear cells
- FCS heat inactivated FCS+ 100 U/ml DNase (100 U/ml; BM) at a cell concentration of 1-2x10 7 /ml and were separated in CD3 + and CD3 cell populations b ⁇ standard AET- sheep red blood cell (sRBC) rosetting.
- sRBC standard AET- sheep red blood cell
- SRBC-CD3 * cells were depleted of sRBC b ⁇ treatment with ACK RBC I ⁇ sing buffer and cultured on laminin coated plates in media containing one of seven c ⁇ tokine cocktails (#1-7) with or without INDINAVIR (CRIXI AN) (7 ⁇ U) (Merck, Whitehouse Station, NJ).
- the cocktails were: (1) IL-2; (2) IL-2, IL-6, and OSM; (3) IL-2, IL-6, IL-7, OSM, and SCF; (4) IL-2, IL-6, IL-7, OSM, SCF, and fit 3;
- T and NK cell-depleted population was further depleted of monoc ⁇ te/macrophages with 20-30 minutes of plastic adherence.
- the non-adherent population was then selected for CD34 + cells using immunomagnetic anti-CD34 Mab and/or anti-AC133 Mab coupled beads.
- An aliquot of CD34/AC133 * cells was anal ⁇ zed b ⁇ flow c ⁇ tometr ⁇ for purit ⁇ and the population was reselected if more than 1 % CD3 * cells were present.
- CD34/AC133* cells were added to culture wells, as well as cultured alone in 96 RB laminin coated wells at 5,000 cells/well in various c ⁇ tokine containing media.
- CD34/AC133 * cells were tagged with the fluorescent marker 5-chlorometh ⁇ lfluorescein diacetate (CMFDAKMolecular Probes, Eugene, OR) as per manufacturer instructions prior to adding to I ⁇ mph node fragment containing wells.
- CMFDAKMolecular Probes Molecular Probes, Eugene, OR
- LNF wells treated with the various c ⁇ tokine combinations were not pulsed with CD34/AC133 * cells to serve as CD34+ progenitor cell controls.
- LNFs (1 -2 mm) were then placed (1-6 LNFs/well) on laminin (30 //g/ml; Gibco/Life Science Products) coated wells (24 or 12 well plates) in 75-200 ⁇ l of media, covered with sterile glass cover slips and incubated at 37°C for 1 hr.
- Cytokine-containing media in some cases ⁇ INDINAVIR;
- LNFs #1 (a) only; #2 (a+b + d); #3 (a-e); #4 (a-f); #5 (a-g); #6 (a-c plus e-h) and #7 (a+b+h).
- the LN material was placed in the bottom of the upper chamber of a transwell plate containing
- CD34 * stem cells were added to LN material containing wells (10,000-70,000/well) and monitored by a variety of parameters for indicators of lymphopoiesis.
- CD34 + stem cells were added to LNF containing wells several times over approximatel ⁇ a 1 month period.
- RNA deoxyribonucleic acid
- TRIAZOL Life Technologies, Rockville, MD
- the cells were pelleted b ⁇ centrifugation and resuspended in 1 ml of TRIAZOL. To the suspension was added 200 ⁇ l of chloroform.
- the ⁇ ield of the above-described method was a nucleic acid pellet derived from the cultured cells.
- the next step of the assa ⁇ method was to quantitate the amount of RNA present in the pellet and to determine the purit ⁇ of the ⁇ ield using ultraviolet spectroscopy using an absorbance ratio of A260/280. This ratio yields information on the nucleic acid to protein absorbance present in the sample.
- the nucleic acid sample was treated with 3U DNase for 30 minutes at 37°C to digest an ⁇ deox ⁇ ribonucleic acid that was present in the sample.
- RNA was synthesized from the isolated RNA.
- the cDNA was constructed using the reverse transcriptase protocol from the SUPERSCRIPT KIT (Life Technologies, Rockville, MD). According to this protocol, in a 20 ⁇ L reaction volume was placed: the purified RNA and 100 Units of
- the solution was brought to a final concentration of the following compounds: 50 mM Tris-HCI, 75 mM KCI, 3 mM MgCI 2 , 2 mM DTT, and 500 ⁇ M of the four deox ⁇ ribonucleosides (dNTPs).
- dNTPs deox ⁇ ribonucleosides
- the resulting product was used as a template for the pol ⁇ merase chain reaction.
- the primers used in the reaction were: Forward Primer Sequence: 5'-GGCACACCCTTTCCTTCTCTG-3'
- the PCR conditions were as follows: an initial heating step at 94° C for 2 minutes followed b ⁇ 56°C for 2 minutes.
- the ther oc ⁇ cler in which the PCR samples were inserted were processed for 35 c ⁇ cles.
- the c ⁇ cles consisted of the following steps: first, a round of heating for 30 seconds at 94°C, then a 30 second heating round at 56°C, and then a heating round for 1 minute at 72°C.
- PCR assay 5 ⁇ l of cell lysate (50,000 cells) was added to 20 ⁇ l of master PCR mix.
- the master mix consisted of 2.5 ⁇ l of 10X PCR Buffer; 1.75 ⁇ l 50mM MgCI 2 ; 0.5 ⁇ l 10mM dNTP; 1 ⁇ l 12.5 ⁇ M 5' sj primer; 1 ⁇ l 12.5 ⁇ M 3' sj primer; 1 ⁇ l 3.75 ⁇ M probe; 0.25 ⁇ l 5U/ ⁇ l Taq; 0.125 ⁇ l of BD636 reference; and, 1 1.875 ⁇ l of water for a total volume of 20 ⁇ l.
- T I ⁇ mphocytes T I ⁇ mphoc ⁇ te precursor cells.
- Assessment of HIV viral load was performed b ⁇ ELISA, in which the p24 antigen was measured using the commercially available HIV-1 p24 Antigen Assay (Coulter Corporation, Miami, FL).
- Subject R021898 had CD4 count of ⁇ 50, a high viral load, and was insensitive to INDINAVIR.
- An HIV uninfected individual was used as a control.
- the procedure used to generate the mature T I ⁇ mphoc ⁇ tes was as follows. LNF fragments were isolated and cocultured with CD34 + T cell progenitor cells as described above. Additionally, several different controls were generated for use in the anal ⁇ sis. Cellular growth of the LN material alone, the CD34 * cells alone, and the coculture of I ⁇ mph node material plus CD34+ progenitor cells were monitored for viabilit ⁇ using standard cell culture techniques, such as th ⁇ midine blue d ⁇ e anal ⁇ sis.
- the coculture of LNF fragments and CD34 + progenitor cells was conducted in vitro under seven different T cell differentiating c ⁇ tokine cocktails either in the presence or absence of INDINAVIR.
- the cocktails were:
- FIGURE 2 shows a number of FACS results obtained from the cells of Subject R021898 that were grown using the culture methods described herein.
- FIGURE 2 graphs A and B show the presence of CD3 * CD8 * (56.5%) and CD3 * CD4 * (9.1 %), respectivel ⁇ which were obtained from PBMCs on da ⁇ #1.
- FIGURE 2 graphs C and D examined cells taken from the isolated LN material which showed CD3 * CD8 * (0.5%) and CD3 + CD4 + (0.1 %), respectivel ⁇ .
- FIGURE 2 graph E examined the expression of CD4 * vs. CD8 + cells from the LN material on da ⁇ 14, just prior to the addition of the CD34 * cells, in the presence of T cell cocktail No. 1.
- the cocktail used here was a control to detect the presence or absence of contaminating T cells in the isolated LN material.
- those cells that displa ⁇ ed both the CD4 and CD8 markers appeared in the upper right quadrant of the graph (Stage 1 , 2, and 3 of developing double positive T cells). This quadrant in graph E shows onl ⁇ a population of 2.2% cells with these markers.
- Graph F shows FACS results looking at the expression of CD3 and CD4 markers. This graph shows a reading of 8.9% for cells displaying both markers (single positive mature CD3+CD4+ T cells).
- CD4 + CD8 + double positive cells are also present.
- substantial populations of CD4 + or CD8 + cells were also present.
- the displa ⁇ ed results of graph K are t ⁇ pical of developing th ⁇ moc ⁇ te population obtained from a health ⁇ subject.
- the results discussed show that the methods described herein are capable of producing a viable population of T cells expressing both CD4 and CD8 markers.
- the results shown in FIGURE 3 demonstrate the complex expression of CD3, CD4 and CD8 receptors which occur during T cell differentiation.
- the level of expression of CD8 increased along the ⁇ -axis
- the level of expression of CD4 increased along the x-axis
- the level of expression of CD3 increased along the z-axis (oriented toward the viewer).
- the 3-D cube on the left represents CD34 + progenitor cells cocultured with LN stroma in c ⁇ tokine combination #1, there were only stage 4 single positive mature T cells present, single positive CD3 * C08 + T cells are represented along the rear left plane and single positive CD3 + CD4 + T cells are represented along the forward plane.
- stages 1, 2, and 3 There were transitional stage 4 single positive mature T cells present along the base of the double positive population along with mature single positive CD3 + CD8 + T cells which are represented along the rear left plane and mature single positive CD3 * CD4 * T cells which are represented along the forward plane.
- the first column represents lymphoc ⁇ tes purified from an HIV negative donor.
- the remaining columns show results from various samples taken from subject R021898.
- the second column shows the Stimulation Index results from LN material taken from da ⁇ 1, which indicate there was onl ⁇ limited incorporation of the label.
- the remaining columns indicate the Stimulation Index measurements taken on da ⁇ 80 for cocultured cells with T cell differentiating cocktails Nos. 1 through 6.
- the third column (LN d80#1), cells cultured in the presence of cocktail No. 1 produced cells that responded to PHA stimulation, but onl ⁇ responded nominally compared to Day#1 LNMCs.
- the results shown in the sixth column showed the highest stimulation response for all of the culture conditions. These cells produced a Stimulation Index reading of (25) when stimulated with PHA.
- the results from the seventh (LN d80#5) and eighth (LN d80#6) columns were less pronounced but still well above the LNMC d#1 levels of approximatel ⁇ (3).
- the seventh column had measurements of (10) for PHA stimulation.
- the eighth column also had a (10) for PHA stimulation.
- FIGURE 5 shows a study similar to that shown in FIGURE 4, however the I ⁇ mphoc ⁇ tes were stimulated b ⁇ allo-antigens.
- L ⁇ mphoc ⁇ te response to stimulation by allo-antigen is MHC-restricted but is not antigen specific at the TCR receptor.
- Cocktails No. 3, 4, 5, and 6, showed increasing levels of responsiveness to allo-antigen compared to
- FIGURE 6 shows a stud ⁇ similar to that shown in FIGURE 4, however, the antigens used in FIGURE 6 are thought to stimulate different populations of T cells.
- Staphylococcus aureus Enterotoxin-A (SE ) stimulates V chain families 1, 3, 10, 11, and 17, while Staphylococcus aureus Enterotoxin-B (SE-B) stimulates V chain families 3, 7, 8, and 17. Accordingl ⁇ , the results of this experiment permit one to assess which V chain families were represented in the mature T cells including those differentiated in culture.
- Cells from this culture responded well to SE-A but showed almost no response to SE-B stimulation (V ⁇ 7, 8 cells were not present or not responding in the tested culture).
- a pattern of skewed responsiveness is noted during advanced HIV infection.
- the Stimulation Index from cells in column 4 (LNd80#2) showed a response to both SE-A and SE-B stimulation, although this response was well below that of the positive control.
- the results shown in columns 5 and 6 (LNd80#3 and LNd80#4, respectivel ⁇ ) showed antigen induced stimulation response comparable to those of the positive control. Cocktail No.
- the mature T cells are administered to the subject so as to suppl ⁇ the subject with viable, HIV-free T cells.
- the administration of the cocultured T cells occurs subsequent to an aggressive antiviral chemotherapeutic regime to protect the cocultured HIV-free T cells from infection.
- a subject with an immune system damaged b ⁇ chemotherap ⁇ is treated with the methods of the present invention to provide the subject with a viable population of mature T cells.
- a population of mature T cells is generated from CD34 + stem cells and lymphoid tissue as described above.
- Mature T cells are isolated from the coculture and administered to the subject.
- a course of hemopoietic differentiation stimulating compounds such as EPO are also administered at efficacious concentrations to stimulate the generation of erythroid cells.
- Example 11 Reconstitution of a Human Immune System Damaged by Radiotherapy
- CD34 + cells are acquired from a donor shown to be compatible with the host patient's immune system.
- the exogenous stem cells are differentiated according to the methods described above. The result is a patient with a reconstituted immune system.
- the expression vector is introduced using standard molecular biology techniques well known in the art.
- the expression vector also contains a drug selection marker, such as the tetracycline resistance marker, so that cells containing a functional cop ⁇ of the expression vector ma ⁇ be selected for using tetrac ⁇ cline selection.
- Mature CD4 + T cells are vulnerable to HIV infection.
- the mature CD4 * cells generated in this Example are prevented from producing virus because the ⁇ contain the expression vector with the tat antisense sequence. This sequence prevents the expression of this essential viral protein. Accordingl ⁇ , the mature CD4 * cells administered to the HIV patient are protected from HIV infection.
- a cocktail of T cell differentiating cytokines is administrated to I ⁇ mphoid tissue in the subject to be treated.
- the cocktail of T cell differentiating cytokines contains: IL-2, IL-6, IL-7, OSM, SCF, and fit 3.
- the cocktail is administered by injection according to basic surgical techniques well known in the art. Specifically, a catheter is introduced through the skin and positioned in a lymph node located under the right arm of the subject. Following insertion of the catheter, the cocktail is administered.
- the components of the cytokine cocktail function to convert the tissue of the I ⁇ mph node into a microenvironment in which migrating CD34 + stem cell differentiate into mature T cells.
- SEQ ID NO. 1 Primer Sequence: 5'-GGCACACCCTTTCCTTCTCTG-3"
- SEQ ID NO. 2 Primer Sequence: 5'-GCAGGTCCTGGCTGTAGAAGC-3'
- SEQ ID NO. 3 tat/rev Exon I of HIV 5'-CCAGGAAGUCAGCCUAAAA-3'
- SEQ ID NO. 4 trgene sequence fragment 5' CAGACUCAUCAAGCUUCUC-3'
- SEQ ID NO. 5 HIV riboz ⁇ me sequence
- SEQ ID NO. 6 HIV riboz ⁇ me sequence 5'-GUCUGAGUAAAGCAGGAGUGCCUGAGUAGUCUUCGAAGAG-3'
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU17531/01A AU1753101A (en) | 1999-10-29 | 2000-10-27 | Method of in vitro T cell differentiation of CD34+ progenitor cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16257499P | 1999-10-29 | 1999-10-29 | |
US60/162,574 | 1999-10-29 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2001032841A2 WO2001032841A2 (en) | 2001-05-10 |
WO2001032841A3 WO2001032841A3 (en) | 2002-02-07 |
WO2001032841A9 true WO2001032841A9 (en) | 2002-07-04 |
Family
ID=22586221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/029655 WO2001032841A2 (en) | 1999-10-29 | 2000-10-27 | Method of in vitro t cell differentiation of cd34+ progenitor cells |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU1753101A (en) |
WO (1) | WO2001032841A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2864546A1 (en) * | 2003-12-24 | 2005-07-01 | Assist Publ Hopitaux De Paris | METHOD OF IDENTIFYING AND PREPARING T REGULATORY / SUPPRESSOR T CELLS, COMPOSITIONS AND USES |
AU2009311232B2 (en) | 2008-11-07 | 2014-10-30 | Sunnybrook Health Sciences Centre | Human progenitor T-cells |
WO2011068962A1 (en) * | 2009-12-03 | 2011-06-09 | The University Of Utah Research Foundation | Methods for generating t lymphocytes from hematopoietic stem cells |
CN111718899B (en) * | 2020-06-19 | 2021-11-23 | 珠海贝索细胞科学技术有限公司 | Culture method for in vitro induced NK (natural killer) cells after resuscitation of cryopreserved human PBMCs (peripheral blood mononuclear cells) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2131368A1 (en) * | 1992-03-04 | 1993-09-16 | Chu-Chih Shih | Culturing of hematopoietic stem cells and their genetic engineering |
DE4240635C2 (en) * | 1992-12-03 | 1997-07-10 | Lothar Prof Dr Kanz | Multiplication of hematopoietic progenitor cells ex vivo and compositions of hematopoietic growth factors |
US5677139A (en) * | 1995-04-21 | 1997-10-14 | President And Fellows Of Harvard College | In vitro differentiation of CD34+ progenitor cells into T lymphocytes |
EP0889693A1 (en) * | 1996-02-21 | 1999-01-13 | Cira Technologies Inc. | Cellular immunotherapy |
IT1293827B1 (en) * | 1997-08-07 | 1999-03-10 | Dompe Spa | METHOD FOR EX VIVO EXPANSION OF HEMATOPOIETIC STEM CELLS |
EP1068298A1 (en) * | 1998-02-27 | 2001-01-17 | Anticancer, Inc. | In vitro model for viral infection and immune response |
CN1180079C (en) * | 1998-11-12 | 2004-12-15 | 基质细胞有限责任公司 | Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices |
-
2000
- 2000-10-27 WO PCT/US2000/029655 patent/WO2001032841A2/en active Application Filing
- 2000-10-27 AU AU17531/01A patent/AU1753101A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001032841A3 (en) | 2002-02-07 |
WO2001032841A2 (en) | 2001-05-10 |
AU1753101A (en) | 2001-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1135463B1 (en) | Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices | |
US6734014B1 (en) | Methods and compositions for transforming dendritic cells and activating T cells | |
Glienke et al. | GMP-compliant manufacturing of TRUCKs: CAR T cells targeting GD2 and releasing inducible IL-18 | |
EP2177601A1 (en) | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance | |
WO1996033265A1 (en) | In vitro differentiation of cd34+ progenitor cells into t lymphocytes | |
KR20080056266A (en) | Method for production of t cell population | |
US20130323832A1 (en) | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance | |
US20230123731A1 (en) | Mitochondria-enriched genetically engineered cells and uses thereof | |
JP2018531022A (en) | Methods for generating modified human primary blood dendritic cell lines | |
JP2018531022A6 (en) | Methods for generating modified human primary blood dendritic cell lines | |
US20070196335A1 (en) | Immune Modulation By Regulating Expression Of The "Minor" Gene In Immune Dendritic Cells | |
AU2266097A (en) | Methods and compositions for transforming dendritic cells and activating t cells | |
US7494807B2 (en) | Mammalian megakaryocyte progenitor cell | |
US5837507A (en) | Hox-induced enhancement of in vivo and in vitro proliferative capacity and gene therapeutic methods | |
WO2001032841A9 (en) | Method of in vitro t cell differentiation of cd34+ progenitor cells | |
Sportoletti et al. | Interleukin-7–engineered mesenchymal cells: in vitro effects on naïve T-cell population | |
US20050208025A1 (en) | Enhancement of hematopoietic stem cell survival | |
WO1997012052A1 (en) | Transduction of hematopoietic cells by viral vector and a cationic lipid | |
CN116874609A (en) | Novel modularized universal CAR-T cell and preparation method thereof | |
WO1997022708A1 (en) | Primate cluster-forming embryonic hematopoietic stem cells | |
Peault | THE ORIGIN OF HUMAN HEMATOPOIETIC STEM CELLS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/6-6/6, DRAWINGS, REPLACED BY NEW PAGES 1/6-6/6; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |